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Introduction {#jdi242-sec-0005}
============

Incretin‐related drugs include glucagon‐like peptide‐1 (GLP‐1) receptor agonists and dipeptidyl peptidase‐4 (DPP‐4) inhibitors, which suppress glucagon secretion[1](#jdi242-bib-0001 jdi242-bib-0002){ref-type="ref"}, confer a β‐cell protective effect[3](#jdi242-bib-0003 jdi242-bib-0004 jdi242-bib-0005){ref-type="ref"} and do not alter bodyweight[6](#jdi242-bib-0006 jdi242-bib-0007){ref-type="ref"}. The aforementioned effects have not been observed with conventional drugs, and these drugs are expected to provide an entirely new treatment option for diabetes. Liraglutide, a GLP‐1 receptor agonist, was approved in Europe in June 2009 and in Japan and the USA in January 2010. In the phase III clinical trial of the Liraglutide Effect and Action in Diabetes (LEAD) study, the safety and effectiveness of liraglutide, as a monotherapy or in various combination therapies with oral hypoglycemic agents (OHAs), was evaluated[8](#jdi242-bib-0008 jdi242-bib-0009 jdi242-bib-0010 jdi242-bib-0011 jdi242-bib-0012 jdi242-bib-0013 jdi242-bib-0014){ref-type="ref"}. In both studies, liraglutide has shown good blood glucose control compared with control groups. Furthermore, effects such as weight loss, decrease in systolic blood pressure, improved pancreatic β‐cell function and improved cardiovascular markers have been confirmed. In the clinical development program for liraglutide in Japan, two confirmatory tests were carried out[15](#jdi242-bib-0015 jdi242-bib-0016 jdi242-bib-0017 jdi242-bib-0018){ref-type="ref"}. One study compared the efficacy and safety of liraglutide monotherapy and glibenclamide monotherapy[15](#jdi242-bib-0015 jdi242-bib-0016){ref-type="ref"}, and the other compared the efficacy and safety of liraglutide combination therapy with sulfonylurea drugs, and sulfonylurea drug monotherapy[17](#jdi242-bib-0017 jdi242-bib-0018){ref-type="ref"}. Both have confirmed the superior hypoglycemic action and safety of liraglutide.

Liraglutide has excellent hypoglycemic effects and can be used in hyperglycemic patients, who have maintained some insulin secretion capacity in response to hyperglycemia. From a long‐term perspective, liraglutide should be aggressively used shortly after diabetes onset because of its protective effects on pancreatic β‐cells that could prevent their dysfunction[3](#jdi242-bib-0003 jdi242-bib-0004 jdi242-bib-0005){ref-type="ref"}. In the present study, we compared liraglutide effects between the following two groups: (i) drug‐naïve patients or those with a relatively short diabetic history who switched from OHAs; and (ii) those with a measureable diabetic progression who switched from insulin. In addition, the suitable timing of liraglutide administration in patients with type 2 diabetes in Japan was evaluated.

Insulin has the most potent hypoglycemic effects and is used widely in diabetes management. However, insulin induces hypoglycemia and weight gain because of its fat accumulation effect[19](#jdi242-bib-0019){ref-type="ref"}. Because liraglutide treatment can reduce bodyweight[6](#jdi242-bib-0006 jdi242-bib-0007){ref-type="ref"} and is associated with reduced hypoglycemia, weight loss and a lower risk of hypoglycemia are expected on switching to liraglutide from insulin. To establish standards for liraglutide therapy, we compared background characteristics of both a successful and failed group of patients who switched to liraglutide from insulin.

Materials and Methods {#jdi242-sec-0006}
=====================

Patients with type 2 diabetes who visited to Osaka Red Cross Hospital (Osaka, Japan) between June 2010 and August 2011, and started liraglutide treatment were observed in the present study. Type 2 diabetic patients treated with diet therapy with or without OHAs and/or insulin, had glycated hemoglobin (HbA~1c~) concentrations \>5.5 and \<15.8%, were aged between 24 and 87 years, and had bodyweight \>40 kg were included in the present study. Patients were excluded if they had detectable glutamic acid decarboxylase antibody, impaired hepatic function, significant cardiovascular disease (heart failure, coronary artery disease or uncontrolled hypertension) or non‐stabilized proliferative retinopathy. Before liraglutide administration, 82 patients were treated with insulin (64 patients with multiple daily injection and 18 with single basal injections), 128 patients were treated with OHAs, including sulfonylurea (62 patients), biguanide (70 patients), thiazolidinedione (30 patients), alpha‐glucosidase inhibitor (11 patients), phenylalanine derivative (7 patients) and DPP‐4 inhibitor (14 patients). In outpatients, the initial liraglutide dose was 0.3 mg, which was increased to 0.6 mg after 1 week. In hospitalized patients, after resolving glucose toxicity with intensive insulin therapy, the initial liraglutide dose was 0.3 mg, which was increased to 0.6 mg after 3 days. Insulin was discontinued on liraglutide administration, whereas OHAs were tapered or added based on each physician\'s recommendation. Responders included patients with improvement in HbA~1c~ or glycosylated albumin (Gly‐A) levels measured during a 4‐month observation period, or those with HbA~1c~ concentrations \<6.5% after switching to liraglutide from insulin. HbA~1c~ values were defined by the National Glycohemoglobin Standardization Program (NGSP) standards.

Ethics {#jdi242-sec-0007}
------

Informed consent was obtained from all patients before study initiation. The present study was approved by the relevant ethics committee and was carried out in accordance with the Declaration of Helsinki.

Statistical Analyses {#jdi242-sec-0008}
--------------------

Statistical analyses were carried out using the StatView 5.0 software (SAS Institute, Inc., Cary, NC, USA). Differences between groups were assessed using paired or unpaired two‐tailed Student\'s *t*‐tests. Differences in glycemic control improvement and changes in bodyweight between the drug‐naïve/previous OHA group and the group that switched from insulin was analyzed by [anova]{.smallcaps}. Values of *P* \< 0.05 were considered to be statistically significant.

Results {#jdi242-sec-0009}
=======

Patients included 74 males and 81 females (*n* = 155), and their characteristics are shown in Table [1](#jdi242-tbl-0001){ref-type="table-wrap"}. Compared with the drug‐naïve/previous OHA group, the group that switched from insulin showed longer diabetes history, lower body mass index (BMI) values and lower C‐peptide immunoreactivity (CPR) levels, suggesting diabetes progression. Improvement in blood glucose levels was confirmed in 122 of the 155 patients, and 37 of 122 (30.3%) and 60 of 122 (49.2%) patients achieved HbA~1c~ levels of \<6.5 and \<7.0%, respectively. Of these 122 patients, 87 were treated with OHAs, including sulfonylurea in 49, biguanide in 35, thiazolidinedione in 13, alpha‐glucosidase inhibitor in four and phenylalanine derivative in four. Liraglutide was discontinued because of its side‐effects in 13 patients, and no improvement was observed in the remaining 20 patients. Side‐effects included nausea (*n* = 6), discomfort (*n* = 3), dizziness (*n* = 1), anorexia (*n* = 1), abdominal distension (*n* = 1) and stomach ache (*n* = 1). Significant hypoglycemia was not detected in any patients during this study. In the drug‐naïve group, improved blood glucose levels were observed in all nine patients (100%). In the group that switched from OHAs to liraglutide, 56 of 64 patients (88%) found liraglutide to be effective, 3 (5%) discontinued liraglutide because of its side‐effects and 5 (7%) discontinued liraglutide because of no improvement in glycemic control. In the group that switched to liraglutide from insulin, 57 of 82 patients (70%) found liraglutide effective, 10 (12%) discontinued liraglutide because of side‐effects and 15 (18%) discontinued liraglutide because they showed no improvement in glycemic control (Figure [1](#jdi242-fig-0001){ref-type="fig"}).

![The effect on glycemic control in three different groups before administration of liraglutide. White bars indicate the group of responders. Gray and black bars indicate the group of non‐responders that discontinued liraglutide because glycemic control did not improve and the group that discontinued liraglutide because of side‐effects, respectively. OHAs, oral hypoglycemic agents.](jdi-4-069-g1){#jdi242-fig-0001}

###### Characteristics of patients with type 2 diabetes in three different groups divided according to pretreatment status (before administration of liraglutide)

                        Drug naive (*n *=* *9)   Previous OHAs (*n *=* *64)                         Switched from insulin (*n *=* *82)
  --------------------- ------------------------ -------------------------------------------------- -----------------------------------------------------------------------------------------
  Male:female (*n*)     4:5                      35:29                                              35:47
  Inpatients (%)        7/9 (77.8%)              32/64 (50.0%)                                      18/82 (22.0%)
  Age (years)           57.4 ± 4.7               62.7 ± 1.4                                         63.1 ± 1.5
  DM duration (years)   5.8 ± 3.3                12.8 ± 1.0[\*](#jdi242-note-0002){ref-type="fn"}   15.5 ± 1.1[\*\*](#jdi242-note-0002){ref-type="fn"}[†](#jdi242-note-0002){ref-type="fn"}
  BMI (kg/m^2^)         30.3 ± 2.4               29.4 ± 0.7                                         26.2 ± 0.6[\*](#jdi242-note-0002){ref-type="fn"}[‡](#jdi242-note-0002){ref-type="fn"}
  HbA~1c~ (%)           10.3 ± 0.9               9.0 ± 0.2                                          8.6 ± 0.2[\*](#jdi242-note-0002){ref-type="fn"}
  Gly‐A (%)             28.7 ± 4.6               24.1 ± 0.7                                         24.3 ± 0.7
  Fasting CPR (ng/mL)   2.4 ± 0.6                2.5 ± 0.2                                          1.7 ± 0.1[‡](#jdi242-note-0002){ref-type="fn"}
  Maximum CPR (ng/mL)   4.6 ± 0.8                5.1 ± 0.3                                          3.5 ± 0.2[‡](#jdi242-note-0002){ref-type="fn"}
  Delta CPR (ng/mL)     2.0 ± 0.7                2.5 ± 0.3                                          1.7 ± 0.1
  Urine CPR (μg/day)    82.1 ± 19.3              97.1 ± 8.1                                         63.6 ± 5.3[‡](#jdi242-note-0002){ref-type="fn"}

All values are expressed as mean ±* *SEM (*n* = 155).

\**P *\< 0.05, \*\**P *\< 0.01 vs group of drug naïve; †*P *\< 0.05, ‡*P *\< 0.01 vs group of previous oral hypoglycemic agents (OHAs).

BMI, body mass index; CPR, C‐peptide immunoreactivity; DM, diabetes mellitus; Gly‐A, glycosylated albumin; HbA~1c~, glycated hemoglobin.

John Wiley & Sons, Ltd

We compared the effect on glycemic control of responders divided according to the pretreatment status (before liraglutide administration). Compared with the group that switched from insulin (*n* = 57), the group of drug‐naïve/previous OHAs (*n* = 65) showed no difference in age, but the diabetes history tended to be shorter (11.6 ± 1.0 vs 13.5 ± 1.2 years; *P* = 0.11), there was a high proportion of hospitalized patients (53.8 vs 21.1%), high BMI values (29.8 ± 0.7 vs 25.8 ± 0.7 kg/m^2^; *P* \< 0.01), higher fasting CPR levels (2.5 ± 0.2 vs 1.8 ± 0.1 ng/mL; *P* \< 0.01), higher maximum CPR levels (5.1 ± 0.3 vs 3.8 ± 0.2 ng/mL; *P* \< 0.01), higher delta CPR levels before and after breakfast (2.5 ± 0.3 vs 1.9 ± 0.2 ng/mL; *P* \< 0.05), and higher urine CPR levels (93.2 ± 8.0 vs 71.7 ± 6.4 μg/day; *P* \< 0.05), respectively (Table [2](#jdi242-tbl-0002){ref-type="table-wrap"}). During the 4‐month observation period, improvement in HbA~1c~ levels was observed in the drug‐naïve/previous OHA group (from 9.1 ± 0.2 to 7.2 ± 0.2%) and in the group that switched from insulin (from 8.6 ± 0.2 to 7.8 ± 0.2%). Considerable and significant improvements were observed in both groups, and the extent of improvement was significant in the former (Figure [2](#jdi242-fig-0002){ref-type="fig"}a, upper). The improvement in Gly‐A levels was also observed in the drug‐naïve/previous OHAs group (from 24.1 ± 0.9 to 18.7 ± 0.6%) and in the group that switched from insulin (from 24.3 ± 0.9 to 22.0 ± 0.7%). Considerable and significant improvements were observed in both groups, and the extent of improvement was significant in the former (Figure [2](#jdi242-fig-0002){ref-type="fig"}a, lower). With respect to bodyweight, a reduction of 4.5 ± 0.6% was observed in the group of drug‐naïve/previous OHAs, with a reduction of 5.1 ± 0.8% in the group that switched from insulin; a significant improvement was observed in both groups, and the extent was comparable between these two groups without significance (Figure [2](#jdi242-fig-0002){ref-type="fig"}b). The drug‐naïve/previous OHA group showed a higher proportion of hospitalized patients compared with those who switched from insulin (53.8 vs 21.1%); therefore, hospitalization might influence the effects of liraglutide treatment. We then divided patients into subgroups of hospitalized patients and outpatients, and compared the effects of liraglutide treatment in each. In hospitalized patients, substantial improvement was observed in HbA~1c~ levels in the drug‐naïve/previous OHA group (from 9.8 ± 0.4 to 7.3 ± 0.3%) and in the group that switched from insulin (from 10.0 ± 0.6 to 7.8 ± 0.5%). A significant improvement was observed in both groups, and the extent of improvement was comparable between the two without significance. With respect to bodyweight, a 6.6 ± 1.8% reduction was observed in the drug‐naïve/previous OHA group, and a 6.2 ± 1.3% reduction was observed in the group that switched from insulin; a significant improvement was observed in both, but not significant between the two (Figure [2](#jdi242-fig-0002){ref-type="fig"}c, upper). Meanwhile, in the outpatient group, the improvement in HbA~1c~ levels was observed in the drug‐naïve/previous OHA group (from 8.2 ± 0.2 to 7.1 ± 0.2%), and in the group that switched from insulin (from 8.2 ± 0.2 to 7.8 ± 0.2%). A significant improvement was observed in both groups, and the extent was significant in the former. With respect to bodyweight, a 6.6 ± 1.3% reduction was observed in the drug‐naïve/previous OHA group, with a 6.2 ± 1.3% reduction in the group that switched from insulin; a significant improvement was observed in both groups, but was not significant between the two (Figure [2](#jdi242-fig-0002){ref-type="fig"}c, lower).

![(a) The improvement in glycated hemoglobin (HbA~1c~) levels in the group of drug‐naïve/previous oral hypoglycemic agents (OHAs; round) and in the group that switched from insulin (triangle) in the 4‐month observation period (upper panel). The improvement in glycosylated albumin (Gly‐A) levels in the group of drug‐naïve/previous OHAs (round) and in the group that switched from insulin (triangle) in the 4‐month observation period (lower panel). (b) The improvement in percent bodyweight in the group of drug‐naïve/previous OHAs (round) and in the group that switched from insulin (triangle) in the 4‐month observation period. (c) The improvement in HbA~1c~ levels and percent bodyweight in the group of drug‐naïve/previous OHAs (round) and in the group that switched from insulin (triangle) in the 4‐month observation period in hospitalized patients (upper panel). The improvement in HbA~1c~ levels and percent bodyweight in the group of drug‐naïve/previous OHAs (round) and in the group that switched from insulin (triangle) in the 4‐month observation period in outpatients (lower panel). The comparison was carried out by paired two‐tailed Student\'s *t*‐test and repeated [anova]{.smallcaps} tests. All values are expressed as mean ± SEM. BW, bodyweight; N.S., not significant.](jdi-4-069-g2){#jdi242-fig-0002}

###### Characteristics of responders that confirmed improvement in blood glucose levels and non‐responders that discontinued liraglutide on account of its side‐effects or no improvement of glycemic control (divided with respect to pretreatment status before liraglutide administration)

                         Drug‐naïve/previous OHAs   Switched from insulin                                                        
  ---------------------- -------------------------- ----------------------- ---------------------------------------------------- -------------------------------------------------
  Male:female (*n*)      32:33                      7:1                     26:31                                                9:16
  Inpatients (%)         35/65 (53.8)               4/8 (50.0)              12/57 (21.1)                                         6/25 (24.0)
  Age (years)            61.3 ± 1.5                 67.9 ± 2.6              60.3 ± 1.8                                           69.4 ± 2.1[‡](#jdi242-note-0005){ref-type="fn"}
  DM duration (years)    11.6 ± 1.0                 14.9 ± 3.2              13.5 ± 1.2                                           20.2 ± 2.0[‡](#jdi242-note-0005){ref-type="fn"}
  BMI (kg/m^2^)          29.8 ± 0.7                 26.7 ± 0.9              25.8 ± 0.7[\*\*](#jdi242-note-0005){ref-type="fn"}   27.2 ± 1.1
  HbA~1c~ (%)            9.1 ± 0.2                  9.7 ± 0.5               8.6 ± 0.2                                            8.7 ± 0.3
  Gly‐A (%)              24.1 ± 0.9                 28.5 ± 2.7              24.3 ± 0.9                                           24.6 ± 1.0
  Fasting CPR (ng/mL)    2.5 ± 0.2                  2.2 ± 0.3               1.8 ± 0.1[\*\*](#jdi242-note-0005){ref-type="fn"}    1.2 ± 0.2[‡](#jdi242-note-0005){ref-type="fn"}
  Maximum CPR (ng/mL)    5.1 ± 0.3                  4.8 ± 0.4               3.8 ± 0.2[\*\*](#jdi242-note-0005){ref-type="fn"}    3.0 ± 0.3[‡](#jdi242-note-0005){ref-type="fn"}
  Delta CPR (ng/mL)      2.5 ± 0.3                  2.2 ± 0.5               1.9 ± 0.2[\*](#jdi242-note-0005){ref-type="fn"}      1.1 ± 0.1[‡](#jdi242-note-0005){ref-type="fn"}
  Urine CPR (μg/day)     93.2 ± 8.0                 112.4 ± 22.4            71.7 ± 6.4[\*](#jdi242-note-0005){ref-type="fn"}     39.6 ± 6.0[‡](#jdi242-note-0005){ref-type="fn"}
  Insulin dose (U/day)   --                         --                      22.0 ± 1.7                                           32.6 ± 4.4[†](#jdi242-note-0005){ref-type="fn"}

All values are expressed as mean ±* *SEM.

\**P *\< 0.05, \*\**P *\< 0.01 versus responders of drug naïve/previous oral hypoglycemic agents (OHAs); †*P *\< 0.05, ‡*P *\< 0.01 versus responders that switched from insulin.

BMI, body mass index; CPR, C‐peptide immunoreactivity; DM, diabetes mellitus; Gly‐A, glycosylated albumin; HbA~1c~, glycated hemoglobin.
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In the group that changed from OHAs to liraglutide, eight of 64 patients (12.5%) found liraglutide to be ineffective (Figure [1](#jdi242-fig-0001){ref-type="fig"}). We carefully carried out a detailed comparison of background factors between the responders and non‐responders of the drug‐naïve/previous OHA group; however, no significant differences were observed between the two (Table [2](#jdi242-tbl-0002){ref-type="table-wrap"}, left column).

Next, we carried out a study on the group that switched to liraglutide from insulin. As shown in (Figure [1](#jdi242-fig-0001){ref-type="fig"}), 57 of 82 patients (70%) showed improved glycemic control in the group that switched from insulin; in the remaining 25 patients (30%), no improvement was observed or liraglutide was discontinued because of side‐effects. Compared with the non‐responders, the responders were younger (60.3 ± 1.8 vs 69.4 ± 2.1 years; *P* \< 0.01), had a shorter history of diabetes (13.5 ± 1.2 vs 20.2 ± 2.0 years; *P* \< 0.01), had higher fasting CPR levels (1.8 ± 0.1 vs 1.2 ± 0.2 ng/mL; *P* \< 0.01), higher maximum CPR levels (3.8 ± 0.2 vs 3.0 ± 0.3 ng/mL; *P* \< 0.01), higher delta CPR levels before and after breakfast (1.9 ± 0.2 vs 1.1 ± 0.1 ng/mL; *P* \< 0.01), higher urine CPR levels (71.7 ± 6.4 vs 39.6 ± 6.0 μg/day; *P* \< 0.01), and used fewer insulin units per day (22.0 ± 1.7 vs 32.6 ± 4.4 U/day; *P* \< 0.05), respectively (Table [2](#jdi242-tbl-0002){ref-type="table-wrap"}, right column). We focused on individual CPR levels in blood and urine for both responders and non‐responders (Figure [3](#jdi242-fig-0003){ref-type="fig"}a). From this viewpoint, switching to liraglutide from insulin might succeed if fasting CPR was \>2.2 ng/mL, if delta CPR before and after breakfast was \>1.6 ng/mL, and if urine CPR was \>70 μg/day. We also focused on the daily insulin dosage (U/day) and age with respect to switching to liraglutide from insulin (Figure [3](#jdi242-fig-0003){ref-type="fig"}b). In elderly patients, liraglutide was discontinued because of side‐effects in most cases. For patients aged 30--70 years, switching to liraglutide from insulin was effective for those using insulin approximately 20 U/day, although some cases were unsuccessful despite using smaller doses (approximately 10 U/day); most cases were unsuccessful in switching if the amount of insulin per day exceeded 40 U/day, except in some younger patients. Therefore, when switching to liraglutide from insulin, although several cases were observed with some exceptions, a cautious decision with confirming endogenous insulin secretion capacity, age and daily insulin usage should be obtained.

![(a) Comparisons of fasting C‐peptide immunoreactivity (CPR; left panel), delta CPR before and after breakfast (middle panel), and urine CPR (right panel) levels between responders and non‐responders. The comparison was carried out by unpaired two‐tailed Student\'s *t*‐test. Bars indicate mean ± standard error of the mean. NI, no improvement for glycemic control; SE, side‐effects. (b) Investigation and comparison of background factors between responders (white circles) and non‐responders (gray circles, no improvement of glycemic conrol; black circles, side‐effects) after switching to liraglutide from insulin. The vertical axis represents the amount of daily insulin use before switching to liraglutide, and the horizontal axis represents the age.](jdi-4-069-g3){#jdi242-fig-0003}

Discussion {#jdi242-sec-0010}
==========

Type 2 diabetes is a progressive disease, and its pathogenesis includes insulin resistance and insulin secretory dysfunction, which is recognized before disease onset. A decrease by half in pancreatic β‐cell function has been reported on diagnosis[20](#jdi242-bib-0020){ref-type="ref"}, and a 20% decrease at the stage of impaired glucose tolerance[21](#jdi242-bib-0021){ref-type="ref"}. Furthermore, compared with the Western population, the Japanese population is more prone to insulin secretion failure caused by pancreatic β‐cell dysfunction[22](#jdi242-bib-0022){ref-type="ref"}. DPP‐4 inhibitors and GLP‐1 receptor agonists, which are incretin‐related drugs, have a protective effect on pancreatic β‐cells[3](#jdi242-bib-0003 jdi242-bib-0004 jdi242-bib-0005){ref-type="ref"}. Given the long‐term perspective, pancreatic β‐cell dysfunction in diabetic patients can be prevented by relatively early intensive therapy with these agents when postprandial hyperglycemia becomes detectable. In phase III liraglutide clinical trials in Japan, greater improvement in glycemic control was observed in drug‐naïve patients compared with those who switched from oral agents[15](#jdi242-bib-0015){ref-type="ref"}. However, the difference between the liraglutide effects with respect to pretreatment status, including insulin and disease stage, has not been previously reported. Here, we examined and compared the liraglutide effects in type 2 diabetic patients having a relatively shorter diabetic history and were drug‐naïve or previously treated with OHAs, and patients who switched from insulin. Compared with the group that switched from insulin, the drug‐naïve/previous OHA group showed no differences in age, but their diabetes history tended to be shorter, with higher BMI values, higher CPR levels in blood and urine, and particularly, a more pronounced improvement in blood glucose levels with a higher percentage of responders. From point of this view, liraglutide administration in early diabetic patients who have retained some endogenous insulin secretory capacity are more effective. We propose that liraglutide is more effective in earlier diabetic stages. Randomized clinical trials of incretin‐related drugs including liraglutide should be carried out, and by accumulating evidence on optimal hyperglycemia management, a diabetes treatment algorithm should be proposed in the future.

Because insulin exerts a potent hypoglycemic action, a significant risk for hypoglycemia is often observed. Insulin induces fat accumulation in the peripheral adipose tissue by inhibiting lipolysis through hormone‐sensitive lipases[23](#jdi242-bib-0023){ref-type="ref"}, leading to weight gain[19](#jdi242-bib-0019){ref-type="ref"}. Insulin exerts an anorexic effect on the central nervous system[24](#jdi242-bib-0024){ref-type="ref"}; however, insulin‐treated diabetic patients often eat too much for the fear or experience of hypoglycemia attack, which can also lead to weight gain[25](#jdi242-bib-0025){ref-type="ref"}. Diabetic patients are often obese, which is frequently complicated by metabolic syndrome with hypertension or dyslipidemia[26](#jdi242-bib-0026){ref-type="ref"}. Therefore, by using insulin for glycemic control, blood glucose levels per se improve, but weight gain could increase accompanied with hyperlipidemia and hypertension. For example, higher insulin doses in the Veteran Affairs Diabetes Trial were associated with weight gain as well as hypoglycemia, a predictor of cardiovascular mortality and macrovascular outcomes[27](#jdi242-bib-0027){ref-type="ref"}. Liraglutide treatment has been shown to be associated with reduced hypoglycemia, and it promotes weight loss[6](#jdi242-bib-0006 jdi242-bib-0007){ref-type="ref"} by reducing appetite through the suppression of eliminating gastric contents[28](#jdi242-bib-0028){ref-type="ref"} or by acting on the central nervous system[29](#jdi242-bib-0029){ref-type="ref"}. Therefore, switching to liraglutide from insulin reduces hypoglycemia risk, and alleviates dyslipidemia and hypertension because of weight loss. Furthermore, except for basal supported oral therapy, insulin is often injected twice (in morning and evening before meals) or four times in basal‐bolus therapy. Because liraglutide has a half‐life of 13 h, only one injection per day is required, thus relieving patients from multiple daily insulin injections. Therefore, the disadvantages of insulin, such as the risk of hypoglycemia, weight gain and the necessity of multiple injections might be overcome by switching to liraglutide in certain cases. However, liraglutide is not a substitute for insulin. In Japan, during the 4 months (11 June 2010 to 7 October 2010) since the approval of liraglutide, four cases of diabetic ketoacidosis and 16 cases of hyperglycemia have been reported. In 17 out of 20 hyperglycemic cases, the condition resulted after switching to liraglutide from insulin. Therefore, liraglutide should not be considered a substitute for insulin, and the insulin‐dependent status should be determined to gauge whether liraglutide treatment is appropriate before administration. Some facilities carry out glucagon load testing to evaluate endogenous insulin secretion; however, the criterion has not yet been clearly defined. To determine the standard criterion for switching to liraglutide from insulin, we carried out a study on the group that switched to liraglutide from insulin, and carried out a detailed comparison of background factors between the responders and non‐responders. Consequently, switching to liraglutide from insulin might succeed if fasting CPR is \>2.2 ng/mL, delta CPR before and after breakfast is \>1.6 ng/mL, and urine CPR is \>70 μg/day. Several cases were successfully treated even with low CPR levels; however, in such cases, insulin was used to avoid glucose toxicity, which was believed to lower CPR levels. Conversely, the unsuccessful cases were found to show relatively high fasting CPR levels that were complicated by reduced renal function caused by diabetic nephropathy, as decreased CPR clearance might increase apparent CPR levels. By carefully omitting these cases, CPR values might be more accurately delineated. In type 2 diabetic patients, the elderly frequently experience progressive exhaustion of pancreatic β‐cells, but younger people have relatively functional pancreatic β‐cells[30](#jdi242-bib-0030){ref-type="ref"}. The capacity of liraglutide to assist with pancreatic β‐cell proliferation has also been reported to decline with age[31](#jdi242-bib-0031){ref-type="ref"}. We then focused on the age and daily insulin dosage with respect to switching to liraglutide from insulin. Most elderly patients discontinued liraglutide mainly on account of its side‐effects. In patients aged 30--70 years, most found that switching to liraglutide was effective if their daily insulin dosage was approximately 20 U/day; most cases were unsuccessful in switching if the amount of insulin per day exceeded 40 U/day, except in some younger patients. Therefore, switching to liraglutide from insulin might succeed if the patient is not elderly, and if a smaller insulin dose is used. No other reports have described liraglutide use in patients who switched from insulin, and only one report described switching to exenatide from insulin[32](#jdi242-bib-0032){ref-type="ref"}. In that study, 29 diabetic patients switched to exenatide from insulin. Consequently, 18 patients (62%) successfully achieved glycemic control, whereas the remaining 11 (38%) were unsuccessful. However, responders were defined if a HbA~1c~ increase was \<0.5%, and the content of that paper has also received critical comments[33](#jdi242-bib-0033){ref-type="ref"}.

Several exceptions were observed in the present study. In switching from insulin, some patients found liraglutide to be ineffective despite using less insulin (approximately 10 U/day). Liraglutide was ineffective in some drug‐naïve/previous OHA patients, although their CPR levels were high, suggesting that endogenous insulin secretory capacity was well preserved. We could not clearly explain the reason, but can only speculate that the patients\' habits (exercise, TV viewing, smoking and eating habits) during the present study might have directly worsened their glycemic control.

The present study had a limitation on liraglutide dose. In the LEAD test, daily liraglutide usage was 1.2 or 1.8 mg, and dose‐dependent effects were confirmed[8](#jdi242-bib-0008 jdi242-bib-0009 jdi242-bib-0010 jdi242-bib-0011 jdi242-bib-0012 jdi242-bib-0013 jdi242-bib-0014){ref-type="ref"}. In Japan, dose‐dependent improvement in glycemic control using liraglutide was also confirmed[17](#jdi242-bib-0017 jdi242-bib-0018 jdi242-bib-0034){ref-type="ref"}. The magnitude of HbA~1c~ reduction with liraglutide in the present study (a 1.3% reduction in HbA~1c~ using 0.6 mg of liraglutide in 4 months) was comparable with that reported in Japanese patients[34](#jdi242-bib-0034){ref-type="ref"} (a 1.6% reduction in HbA~1c~ using 0.6 mg of liraglutide over 14 weeks) and in non‐Japanese patients[35](#jdi242-bib-0035){ref-type="ref"} (a 0.7% reduction in HbA~1c~ using 0.6 mg of liraglutide over 12 weeks). In the present study, we used a fixed amount of daily liraglutide; that is, 0.6 mg, during the observation period. Improvement in glycemic control was not observed in 20 of 155 patients, and achievement of HbA~1c~ \< 7.0% was not observed in approximately half of the patients. The maximum dose of liraglutide is 0.9 mg in Japan, and some patients believed that the drug effect would increase if 0.9 mg was used, which should be investigated in the future.

In conclusion, the present study showed that liraglutide improved blood glucose levels, which was more pronounced in the drug‐naïve/previous OHA group compared with the group that switched from insulin. In addition, CPR levels, age and the daily insulin dosage were considered important factors when deciding to switch to liraglutide from insulin. Based on these findings, we can establish standards for liraglutide treatment that are appropriate for type 2 diabetic patients.
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